Developer docs
API playgroundTry for free, no card

Search company profiles

Atomo Diagnostics

Full company profile

uuid0005hpp

Namestring
Atomo Diagnostics
Legal namestring
Atomo Diagnostics Limited
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Atomo Diagnostics Limited is an Australian medical device company, founded in 2010 by John Kelly and headquartered in Leichhardt, NSW, that designs and manufactures user-centred rapid diagnostic test (RDT) platforms for point-of-care and self-test applications. The company's core technology integrates a safety lancet, blood-collection and delivery system, and proprietary buffer-delivery mechanism into all-in-one cassette devices to reduce user error and improve test accuracy. Its platform family comprises the AtomoRapid Pascal, Galileo, Elion, Curie and Florey devices, with the Galileo platform holding WHO Prequalification status and Pascal-derived products holding FDA 510(k) clearance and CE Mark certification. The company's flagship finished product is the Atomo HIV Self Test, launched in Australia in 2018 as the first integrated blood-based HIV self-test on the Australian Register of Therapeutic Goods (ARTG 311989), with 99.6% specificity and sensitivity and a 15-minute read time.

Atomo operates a multi-channel business model across four revenue streams. First, finished rapid diagnostic products are sold directly via the Atomo e-commerce store and through Australian pharmacy retail (including Blooms the Chemist, with pharmacist training required), UK retail (Boots, Tesco via Newfoundland Diagnostics), and consumer channels under own and partner brands. Second, OEM cassette supply provides proprietary cassettes to partners such as Lumos Diagnostics (for the FDA-cleared FebriDx respiratory test) and NG Biotech (for the IVDR-approved Precision+ blood pregnancy test). Third, technology licensing and co-development arrangements exist with BBI Solutions, DCN Diagnostics, and Palladium Diagnostics. Fourth, contract manufacturing services are delivered from the Cape Town facility, which is ISO 13485:2016 certified, currently operating at up to 3 million units per year with expansion capability to more than 10 million units per year.

The company serves four primary segments: sexual health and infectious disease testing (HIV, syphilis, respiratory), consumer self-testing, professional point-of-care healthcare settings, and public health programs. The latter channel is anchored by government- and NGO-run vending machine programs (NSW Ministry of Health MyTest, SAMESH Connect, Queensland Positive People Rapid, NAPWHA free-test distribution) and by the Viatris (Mylan) distribution partnership into lower-middle-income markets in Africa, South and Central America, and Asia. Atomo cites regulatory clearance across 40+ countries, cumulative shipments of over 7 million platforms, and a manufacturing footprint configured to serve the PEPFAR goal of 15 million HIV tests sourced from African manufacturers by 2025. The company is publicly listed on the ASX under the ticker AT1 with 11-50 employees.

Short descriptiontext

Atomo Diagnostics is an ASX-listed Australian medical device company that designs and manufactures user-centred rapid diagnostic test platforms (AtomoRapid Pascal, Galileo, Elion, Curie, Florey) and finished blood-based tests, anchored by its WHO-prequalified HIV Self Test and serving consumer retail, OEM partners, and government and NGO public health programs across 40+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLeichhardt, Australia
HQ citystring
Leichhardt
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lateral flow diagnostics, rapid diagnostic devices, point-of-care testing, HIV self-testing, medical device manufacturing
Industry1 code
PRIMARYHLALAIAL
Infectious Disease & STI Testing-to-Treatment with eRx + Pharmacy Fulfillment
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
In-Vitro Diagnostic Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Rapid Diagnostic Test Device Sales
TypeHardware Sales
Description

Sale of finished rapid diagnostic test products marketed under Atomo's own brand (HIV Self Test) or through private labels via partners and regional distributors.

atomodiagnostics.com
2OEM Cassette Supply
TypeHardware Sales
Description

Supply of proprietary diagnostic cassettes to OEM partners (Lumos Diagnostics for FebriDx, NG Biotech for Precision+ pregnancy test) who incorporate them into their own branded products.

atomodiagnostics.com
3Technology Licensing and Co-Development
TypeLicensing Royalties
Description

Partnership arrangements including co-development, technology licensing, and custom design solutions for assay developers. Partners include BBI Solutions, DCN Diagnostics, and Palladium Diagnostics.

atomodiagnostics.com
4Contract Manufacturing
TypeHardware Sales
Description

Manufacturing services at Cape Town facility with capacity up to 3 million units, expandable to 10 million units per year. Includes assay manufacturing, buffer production, and secondary packaging.

atomodiagnostics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales
Pricing details1 tier
1Atomo HIV Self Test consumer retail price
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Recommended retail price: $29.99 per test. Single-use, blood-based rapid HIV test with 99.6% accuracy and 15-minute results.

atomodiagnostics.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Atomo Diagnostics designs, develops, and manufactures integrated, user-centred rapid diagnostic test (RDT) platforms and finished diagnostic products for point-of-care and consumer self-testing applications. Its AtomoRapid™ platform family integrates safety lancets, blood/swab collection, and patented buffer-delivery systems into all-in-one cassettes that reduce user error. The company sells its own Atomo HIV Self Test through e-commerce and pharmacies, supplies proprietary cassettes to OEM partners (Lumos Diagnostics, NG Biotech), and offers co-development, licensing, and contract manufacturing services from its ISO 13485-certified Cape Town facility.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 90% reduction in blood delivery errors compared to traditional lateral flow test kits
+7 more records
Product overview1 text field

Atomo Diagnostics offers a portfolio of rapid diagnostic test platforms and finished products designed for point-of-care and self-testing applications. The AtomoRapid™ platform family includes five distinct devices: Pascal (blood-based with integrated buffer delivery), Curie (swab-based), Galileo (enhanced blood platform with WHO prequalification), Elion (self-test focused), and Florey (modular add-on for existing cassettes). These platforms are differentiated by their integrated components, interlocked user steps, and proprietary blister technology that eliminate common user errors. Finished products commercialized under Atomo's brand or through partners include the Atomo HIV Self Test (99.6% accuracy, 15-minute results), NG Biotech Precision+ Pregnancy Test (IVDR-approved), and Lumos Diagnostics FebriDx (FDA-cleared for respiratory infection differentiation). The company also provides digital health solutions including a mobile application with cloud connectivity and camera-based reader technology for quantitative test analysis.

Product and service10 records
1AtomoRapid™ Pascal
CategoryRDT Platform
Description

Rapid diagnostic test platform with built-in safety lancet, blood collection and delivery system, and integrated buffer delivery mechanism. Interlocked user steps mitigate common user errors. Designed for point-of-care and self-test applications, and supplied to OEM partners such as Lumos Diagnostics (FebriDx) and NG Biotech (Precision+).

2AtomoRapid™ Curie
CategoryRDT Platform
Description

Swab-based testing platform that expands Atomo's range beyond blood-based diagnostics. Consolidates components, integrates blister and lyophilised buffer reagent, and removes the need for manual sample dosing, reducing user steps and improving sample concentration.

3AtomoRapid™ Galileo
CategoryRDT Platform
Description

Rapid diagnostic test platform with integrated safety lancet and unique blood collection and delivery system. WHO prequalified. Improves test performance and usability with interlocked user steps for professional point-of-care and self-test applications.

4AtomoRapid™ Elion
CategoryRDT Platform
Description

Self-test focused platform with built-in safety lancet, innovative blood collection feature, single-action blood and buffer delivery system, and interlocked user steps. Designed specifically for self-test users with focus on unmatched usability.

5AtomoRapid™ Florey
CategoryRDT Platform
Description

Modular blood-based usability upgrade for existing standard lateral flow cassettes. Clips onto existing cassettes providing integrated blood and reagent buffer delivery, improving usability and precision while maintaining compatibility with existing installed manufacturing capacity and regulatory approvals.

6Atomo HIV Self Test
CategoryFinished Diagnostic Product
Description

World's first integrated, blood-based rapid diagnostic test for HIV screening. Delivers results in 15 minutes with 99.6% specificity and sensitivity. Listed on the Australian Register of Therapeutic Goods (ARTG 311989) since 2018. Sold directly to consumers via e-commerce (atomohivtest.com), through Australian pharmacies with required pharmacist training, and via distribution partners in the UK and lower-middle income markets.

7NG Biotech Precision+ Pregnancy Test
CategoryFinished Diagnostic Product
Description

Partner-branded finished product that uses Atomo's Pascal platform as its cassette. First all-in-one at-home blood pregnancy test, IVDR-approved and available across Europe. Results in 5 minutes with higher accuracy than urine-based pregnancy tests. Atomo supplies the proprietary cassette to NG Biotech under an OEM partnership.

8Lumos Diagnostics FebriDx
CategoryFinished Diagnostic Product
Description

Partner-branded finished product that uses Atomo's Pascal platform as its cassette. Rapid test for identifying and differentiating viral and bacterial acute respiratory infections. FDA cleared (US) and CE marked (Europe) with 99% accuracy; demonstrated 80% reduction in antibiotic prescriptions in clinical use.

9Atomo App (Self-Test Mobile Application)
CategoryDigital Health Solution
Description

Custom mobile application for self-test users providing multimedia-based instructions that optimises usability. Interfaces with an AWS portal for oversight and deployment management. Compatible with generic rectangular cassettes or AtomoRapid whole blood cassettes.

10Camera-Based Reader Technology
CategoryDigital Health Solution
Description

Whole-blood cassettes compatible with various readers maximising ease of use, repeatability and accuracy of results for both colormetric and fluorescence-based testing. Features Bluetooth connectivity, WiFi HL7 interface for LIS communication, and cell phone data transport to cloud.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Lumos Diagnostics utilises Atomo's Pascal platform for their FebriDx test, which is FDA-cleared for the US market and CE marked for Europe. FebriDx assists in identifying and differentiating viral and bacterial acute respiratory infections with 99% accuracy, reducing antibiotic prescriptions by 80%.

2NG Biotech
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

NG Biotech utilises Atomo's Pascal platform for their Precision+ pregnancy test, available throughout Europe. The blood-based test offers results in 5 minutes with higher accuracy than urine tests.

atomodiagnostics.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

UK provider of diagnostic tests marketing Atomo's HIV Self Test under their own brand throughout the UK, Western Europe, and Colombia using the Galileo platform.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Viatris markets the Mylan HIV Self Test manufactured by Atomo across lower-middle income markets in Africa, South and Central America, and Asia. Distributed from South Africa to Lesotho, Namibia, Botswana, Zimbabwe, Zambia, Nigeria, Kenya, and Uganda.

Strategic tierSecondaryTypeImplementation/ SI/ Consulting Partner
Description

CDMO partner offering custom antibody development, lateral flow assay development and manufacturing services. Incorporating Atomo platforms into new development projects provides customers with simplified testing workflow and improved product usability.

Strategic tierSecondaryTypeImplementation/ SI/ Consulting Partner
Description

Global leader in IVD CDMO and CRO services based in Carlsbad, California. Specialises in tailored assay devices and lateral flow readers, supporting programs from concept to assay development and platform integration through clinical trials to manufacturing.

7Palladium Diagnostics
Strategic tierSecondaryTypeImplementation/ SI/ Consulting Partner
Description

Assists developers and manufacturers of rapid point-of-care diagnostic devices in bringing technologies to marketplace efficiently and effectively. Participates in next generation rapid diagnostics development.

atomodiagnostics.com
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaboration on development of a pioneering rapid active syphilis test using Atomo's Pascal platform with a unique syphilis antibody assay. The test will distinguish active infections from previously treated cases - a first for the global market. Part of $2.44M CRC-P grant project.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaborating partner in the $2.44M CRC-P grant project for development of rapid active syphilis test with Atomo and Burnet Institute.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

National Association of People with HIV Australia provides free HIV self-tests through hivtest.au website. Purchases tests from Atomo using government funding, offering two free tests initially and two more after six months to encourage ongoing monitoring.

Strategic tierStrategicTypeGTM or Marketing Partner
Description

Social networking platform for LGBT+ community promoting NAPWHA's free HIV self-test initiative at no cost. Amplified visibility and awareness of testing availability across LGBT+ community.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ Distributor
Description

South Australian organisation running Connect Program vending machines providing free HIV self-testing kits in discreet, accessible locations including universities and sex-on-premises sites.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ Distributor
Description

Queensland organisation running Rapid Program vending machines for HIV self-testing distribution across Queensland.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Government body funding and implementing MyTest program - vending machines for HIV self-testing across NSW, Australia. Targeting MSM community and migrant populations.

Strategic tierStrategicTypeChannel Partner/ Reseller/ Distributor
Description

Victorian health organisation planning nationwide expansion of HIV self-testing vending machine program to all Australian states and territories.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-listed developer of rapid diagnostic tests including the OraQuick HIV self-test. Directly comparable as an HIV/sexual-health-focused rapid diagnostics specialist with self-test and professional POC channels across global public health and retail markets.

2Abbott (Rapid Diagnostics / BinaxNOW)
TypeBroad incumbent
Description

Global IVD incumbent with BinaxNOW and other lateral-flow rapid tests sold through retail pharmacy, professional POC, and OEM channels. Competes in the same integrated, user-friendly rapid test category that Atomo serves, but with vastly greater scale and distribution.

TypeDirect peer
Description

Point-of-care diagnostics company whose FebriDx product is built on Atomo's Pascal platform. Competes in rapid infectious-disease and respiratory testing with FDA-cleared products and overlapping professional POC and hospital customers.

TypeBroad incumbent
Description

Large IVD company with Sofia and Triage rapid diagnostic platforms sold to professional POC, hospital, and retail channels. Comparable in rapid lateral-flow assay development, regulatory depth, and assay-portfolio extensibility.

TypeDirect peer
Description

Specialty rapid diagnostics developer focused on infectious disease (HIV, syphilis, dengue) point-of-care tests. Highly comparable as a small-cap, HIV/sexual-health-focused rapid test company serving public health and professional POC markets.

6NG Biotech
TypeDirect peer
Description

French in-vitro diagnostics company that OEM-integrates Atomo's Pascal platform for the IVDR-approved Precision+ blood pregnancy test. Overlaps in blood-based rapid test development, self-test regulatory pathways, and European distribution.

TypeEmerging player
Description

Global lateral flow CDMO and reagent provider offering custom assay development and OEM cassette manufacturing. Comparable as a partner and competitor in OEM-supply relationships for rapid test developers seeking integrated cassette platforms.

TypeEmerging player
Description

Carlsbad-based IVD CDMO/CRO specialising in tailored lateral flow assay devices and readers, from concept through manufacturing. Comparable as a co-development partner and competitor in the custom integrated rapid test platform space.

TypeDirect peer
Description

Public diagnostics company with a portfolio that includes rapid HIV tests and other point-of-care infectious disease assays. Comparable as a small-to-mid-cap rapid diagnostics company with overlapping public health and clinical lab customers.

TypeBroad incumbent
Description

Global IVD leader with broad rapid test, self-test, and digital health offerings. Relevant as a large incumbent competing in integrated user-friendly rapid diagnostics and as a potential strategic acquirer of niche self-test platform companies like Atomo.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Atomo Diagnostics

In-Vitro Diagnostic Devicesatomodiagnostics.com

Atomo Diagnostics is an ASX-listed Australian medical device company that designs and manufactures user-centred rapid diagnostic test platforms (AtomoRapid Pascal, Galileo, Elion, Curie, Florey) and finished blood-based tests, anchored by its WHO-prequalified HIV Self Test and serving consumer retail, OEM partners, and government and NGO public health programs across 40+ countries.

What Atomo Diagnostics does

Atomo Diagnostics Limited is an Australian medical device company, founded in 2010 by John Kelly and headquartered in Leichhardt, NSW, that designs and manufactures user-centred rapid diagnostic test (RDT) platforms for point-of-care and self-test applications. The company's core technology integrates a safety lancet, blood-collection and delivery system, and proprietary buffer-delivery mechanism into all-in-one cassette devices to reduce user error and improve test accuracy. Its platform family comprises the AtomoRapid Pascal, Galileo, Elion, Curie and Florey devices, with the Galileo platform holding WHO Prequalification status and Pascal-derived products holding FDA 510(k) clearance and CE Mark certification. The company's flagship finished product is the Atomo HIV Self Test, launched in Australia in 2018 as the first integrated blood-based HIV self-test on the Australian Register of Therapeutic Goods (ARTG 311989), with 99.6% specificity and sensitivity and a 15-minute read time.

Atomo operates a multi-channel business model across four revenue streams. First, finished rapid diagnostic products are sold directly via the Atomo e-commerce store and through Australian pharmacy retail (including Blooms the Chemist, with pharmacist training required), UK retail (Boots, Tesco via Newfoundland Diagnostics), and consumer channels under own and partner brands. Second, OEM cassette supply provides proprietary cassettes to partners such as Lumos Diagnostics (for the FDA-cleared FebriDx respiratory test) and NG Biotech (for the IVDR-approved Precision+ blood pregnancy test). Third, technology licensing and co-development arrangements exist with BBI Solutions, DCN Diagnostics, and Palladium Diagnostics. Fourth, contract manufacturing services are delivered from the Cape Town facility, which is ISO 13485:2016 certified, currently operating at up to 3 million units per year with expansion capability to more than 10 million units per year.

The company serves four primary segments: sexual health and infectious disease testing (HIV, syphilis, respiratory), consumer self-testing, professional point-of-care healthcare settings, and public health programs. The latter channel is anchored by government- and NGO-run vending machine programs (NSW Ministry of Health MyTest, SAMESH Connect, Queensland Positive People Rapid, NAPWHA free-test distribution) and by the Viatris (Mylan) distribution partnership into lower-middle-income markets in Africa, South and Central America, and Asia. Atomo cites regulatory clearance across 40+ countries, cumulative shipments of over 7 million platforms, and a manufacturing footprint configured to serve the PEPFAR goal of 15 million HIV tests sourced from African manufacturers by 2025. The company is publicly listed on the ASX under the ticker AT1 with 11-50 employees.

Atomo Diagnostics firmographics

Firmographics
Name
Atomo Diagnostics
Legal name
Atomo Diagnostics Limited
Website
https://atomodiagnostics.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Atomo Diagnostics is an ASX-listed Australian medical device company that designs and manufactures user-centred rapid diagnostic test platforms (AtomoRapid Pascal, Galileo, Elion, Curie, Florey) and finished blood-based tests, anchored by its WHO-prequalified HIV Self Test and serving consumer retail, OEM partners, and government and NGO public health programs across 40+ countries.
Ownership category
akta.pro rank

Atomo Diagnostics industry classification

Industry
Product category
In-Vitro Diagnostic Devices
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLALAIAL
Infectious Disease & STI Testing-to-Treatment with eRx + Pharmacy Fulfillment
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms

Keywords

  • Lateral flow diagnostics
  • Rapid diagnostic devices
  • Point-of-care testing
  • HIV self-testing
  • Medical device manufacturing

Where Atomo Diagnostics is headquartered

Location

Headquarters

HQ city
Leichhardt
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Atomo Diagnostics business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales

Revenue model

  1. Rapid Diagnostic Test Device Sales: Sale of finished rapid diagnostic test products marketed under Atomo's own brand (HIV Self Test) or through private labels via partners and regional distributors.
  2. OEM Cassette Supply: Supply of proprietary diagnostic cassettes to OEM partners (Lumos Diagnostics for FebriDx, NG Biotech for Precision+ pregnancy test) who incorporate them into their own branded products.
  3. Technology Licensing and Co-Development: Partnership arrangements including co-development, technology licensing, and custom design solutions for assay developers. Partners include BBI Solutions, DCN Diagnostics, and Palladium Diagnostics.
  4. Contract Manufacturing: Manufacturing services at Cape Town facility with capacity up to 3 million units, expandable to 10 million units per year. Includes assay manufacturing, buffer production, and secondary packaging.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAtomo HIV Self Test consumer retail price

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Atomo Diagnostics product offering

Product offering

Core offering

Atomo Diagnostics designs, develops, and manufactures integrated, user-centred rapid diagnostic test (RDT) platforms and finished diagnostic products for point-of-care and consumer self-testing applications. Its AtomoRapid™ platform family integrates safety lancets, blood/swab collection, and patented buffer-delivery systems into all-in-one cassettes that reduce user error. The company sells its own Atomo HIV Self Test through e-commerce and pharmacies, supplies proprietary cassettes to OEM partners (Lumos Diagnostics, NG Biotech), and offers co-development, licensing, and contract manufacturing services from its ISO 13485-certified Cape Town facility.

Product overview

Atomo Diagnostics offers a portfolio of rapid diagnostic test platforms and finished products designed for point-of-care and self-testing applications. The AtomoRapid™ platform family includes five distinct devices: Pascal (blood-based with integrated buffer delivery), Curie (swab-based), Galileo (enhanced blood platform with WHO prequalification), Elion (self-test focused), and Florey (modular add-on for existing cassettes). These platforms are differentiated by their integrated components, interlocked user steps, and proprietary blister technology that eliminate common user errors. Finished products commercialized under Atomo's brand or through partners include the Atomo HIV Self Test (99.6% accuracy, 15-minute results), NG Biotech Precision+ Pregnancy Test (IVDR-approved), and Lumos Diagnostics FebriDx (FDA-cleared for respiratory infection differentiation). The company also provides digital health solutions including a mobile application with cloud connectivity and camera-based reader technology for quantitative test analysis.

Differentiator

Problem solved

Functional benefit

Products and services

  • AtomoRapid™ Pascal Rapid diagnostic test platform with built-in safety lancet, blood collection and delivery system, and integrated buffer delivery mechanism. Interlocked user steps mitigate common user errors. Designed for point-of-care and self-test applications, and supplied to OEM partners such as Lumos Diagnostics (FebriDx) and NG Biotech (Precision+).
  • AtomoRapid™ Curie Swab-based testing platform that expands Atomo's range beyond blood-based diagnostics. Consolidates components, integrates blister and lyophilised buffer reagent, and removes the need for manual sample dosing, reducing user steps and improving sample concentration.
  • AtomoRapid™ Galileo Rapid diagnostic test platform with integrated safety lancet and unique blood collection and delivery system. WHO prequalified. Improves test performance and usability with interlocked user steps for professional point-of-care and self-test applications.
  • AtomoRapid™ Elion Self-test focused platform with built-in safety lancet, innovative blood collection feature, single-action blood and buffer delivery system, and interlocked user steps. Designed specifically for self-test users with focus on unmatched usability.
  • AtomoRapid™ Florey Modular blood-based usability upgrade for existing standard lateral flow cassettes. Clips onto existing cassettes providing integrated blood and reagent buffer delivery, improving usability and precision while maintaining compatibility with existing installed manufacturing capacity and regulatory approvals.
  • Atomo HIV Self Test World's first integrated, blood-based rapid diagnostic test for HIV screening. Delivers results in 15 minutes with 99.6% specificity and sensitivity. Listed on the Australian Register of Therapeutic Goods (ARTG 311989) since 2018. Sold directly to consumers via e-commerce (atomohivtest.com), through Australian pharmacies with required pharmacist training, and via distribution partners in the UK and lower-middle income markets.
  • NG Biotech Precision+ Pregnancy Test Partner-branded finished product that uses Atomo's Pascal platform as its cassette. First all-in-one at-home blood pregnancy test, IVDR-approved and available across Europe. Results in 5 minutes with higher accuracy than urine-based pregnancy tests. Atomo supplies the proprietary cassette to NG Biotech under an OEM partnership.
  • Lumos Diagnostics FebriDx Partner-branded finished product that uses Atomo's Pascal platform as its cassette. Rapid test for identifying and differentiating viral and bacterial acute respiratory infections. FDA cleared (US) and CE marked (Europe) with 99% accuracy; demonstrated 80% reduction in antibiotic prescriptions in clinical use.
  • Atomo App (Self-Test Mobile Application) Custom mobile application for self-test users providing multimedia-based instructions that optimises usability. Interfaces with an AWS portal for oversight and deployment management. Compatible with generic rectangular cassettes or AtomoRapid whole blood cassettes.
  • Camera-Based Reader Technology Whole-blood cassettes compatible with various readers maximising ease of use, repeatability and accuracy of results for both colormetric and fluorescence-based testing. Features Bluetooth connectivity, WiFi HL7 interface for LIS communication, and cell phone data transport to cloud.

Quantifiable outcome

  • 90% reduction in blood delivery errors compared to traditional lateral flow test kits
  • +7 more outcomes

Companies that use Atomo Diagnostics

Customer profile

Named customers10 records

Segments5 records

Ideal customer profiles4 records

Atomo Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

Feature8 records

Atomo Diagnostics partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core, secondary and strategic.

  • Lumos DiagnosticscoreOEM/ Whitelabel/ Licensing PartnerLumos Diagnostics utilises Atomo's Pascal platform for their FebriDx test, which is FDA-cleared for the US market and CE marked for Europe. FebriDx assists in identifying and differentiating viral and bacterial acute respiratory infections with 99% accuracy, reducing antibiotic prescriptions by 80%.
  • NG BiotechcoreOEM/ Whitelabel/ Licensing PartnerNG Biotech utilises Atomo's Pascal platform for their Precision+ pregnancy test, available throughout Europe. The blood-based test offers results in 5 minutes with higher accuracy than urine tests.
  • Newfoundland DiagnosticscoreChannel Partner/ Reseller/ DistributorUK provider of diagnostic tests marketing Atomo's HIV Self Test under their own brand throughout the UK, Western Europe, and Colombia using the Galileo platform.
  • Viatris (Mylan)coreChannel Partner/ Reseller/ DistributorViatris markets the Mylan HIV Self Test manufactured by Atomo across lower-middle income markets in Africa, South and Central America, and Asia. Distributed from South Africa to Lesotho, Namibia, Botswana, Zimbabwe, Zambia, Nigeria, Kenya, and Uganda.
  • BBI SolutionssecondaryImplementation/ SI/ Consulting PartnerCDMO partner offering custom antibody development, lateral flow assay development and manufacturing services. Incorporating Atomo platforms into new development projects provides customers with simplified testing workflow and improved product usability.
  • DCN DiagnosticssecondaryImplementation/ SI/ Consulting PartnerGlobal leader in IVD CDMO and CRO services based in Carlsbad, California. Specialises in tailored assay devices and lateral flow readers, supporting programs from concept to assay development and platform integration through clinical trials to manufacturing.
  • Palladium DiagnosticssecondaryImplementation/ SI/ Consulting PartnerAssists developers and manufacturers of rapid point-of-care diagnostic devices in bringing technologies to marketplace efficiently and effectively. Participates in next generation rapid diagnostics development.
  • Burnet InstitutestrategicStrategic or Co-development PartnerCollaboration on development of a pioneering rapid active syphilis test using Atomo's Pascal platform with a unique syphilis antibody assay. The test will distinguish active infections from previously treated cases - a first for the global market. Part of $2.44M CRC-P grant project.
  • IDE GroupstrategicStrategic or Co-development PartnerCollaborating partner in the $2.44M CRC-P grant project for development of rapid active syphilis test with Atomo and Burnet Institute.
  • NAPWHAcoreChannel Partner/ Reseller/ DistributorNational Association of People with HIV Australia provides free HIV self-tests through hivtest.au website. Purchases tests from Atomo using government funding, offering two free tests initially and two more after six months to encourage ongoing monitoring.
  • GrindrstrategicGTM or Marketing PartnerSocial networking platform for LGBT+ community promoting NAPWHA's free HIV self-test initiative at no cost. Amplified visibility and awareness of testing availability across LGBT+ community.
  • SAMESHsecondaryChannel Partner/ Reseller/ DistributorSouth Australian organisation running Connect Program vending machines providing free HIV self-testing kits in discreet, accessible locations including universities and sex-on-premises sites.
  • Queensland Positive PeoplesecondaryChannel Partner/ Reseller/ DistributorQueensland organisation running Rapid Program vending machines for HIV self-testing distribution across Queensland.
  • NSW Ministry of HealthcoreChannel Partner/ Reseller/ DistributorGovernment body funding and implementing MyTest program - vending machines for HIV self-testing across NSW, Australia. Targeting MSM community and migrant populations.
  • Thorne Harbour HealthstrategicChannel Partner/ Reseller/ DistributorVictorian health organisation planning nationwide expansion of HIV self-testing vending machine program to all Australian states and territories.

Scale indicators14 records

Recent moves6 records

Expansion highlights7 records

Atomo Diagnostics competitors and assessment

Company assessment

Direct peers

  • OraSure Technologies: US-listed developer of rapid diagnostic tests including the OraQuick HIV self-test. Directly comparable as an HIV/sexual-health-focused rapid diagnostics specialist with self-test and professional POC channels across global public health and retail markets.
  • Lumos Diagnostics: Point-of-care diagnostics company whose FebriDx product is built on Atomo's Pascal platform. Competes in rapid infectious-disease and respiratory testing with FDA-cleared products and overlapping professional POC and hospital customers.
  • Chembio Diagnostics: Specialty rapid diagnostics developer focused on infectious disease (HIV, syphilis, dengue) point-of-care tests. Highly comparable as a small-cap, HIV/sexual-health-focused rapid test company serving public health and professional POC markets.
  • NG Biotech: French in-vitro diagnostics company that OEM-integrates Atomo's Pascal platform for the IVDR-approved Precision+ blood pregnancy test. Overlaps in blood-based rapid test development, self-test regulatory pathways, and European distribution.
  • Trinity Biotech: Public diagnostics company with a portfolio that includes rapid HIV tests and other point-of-care infectious disease assays. Comparable as a small-to-mid-cap rapid diagnostics company with overlapping public health and clinical lab customers.

Broad incumbents

  • Abbott (Rapid Diagnostics / BinaxNOW): Global IVD incumbent with BinaxNOW and other lateral-flow rapid tests sold through retail pharmacy, professional POC, and OEM channels. Competes in the same integrated, user-friendly rapid test category that Atomo serves, but with vastly greater scale and distribution.
  • QuidelOrtho: Large IVD company with Sofia and Triage rapid diagnostic platforms sold to professional POC, hospital, and retail channels. Comparable in rapid lateral-flow assay development, regulatory depth, and assay-portfolio extensibility.
  • Roche Diagnostics: Global IVD leader with broad rapid test, self-test, and digital health offerings. Relevant as a large incumbent competing in integrated user-friendly rapid diagnostics and as a potential strategic acquirer of niche self-test platform companies like Atomo.

Emerging players

  • BBI Solutions: Global lateral flow CDMO and reagent provider offering custom assay development and OEM cassette manufacturing. Comparable as a partner and competitor in OEM-supply relationships for rapid test developers seeking integrated cassette platforms.
  • DCN Diagnostics: Carlsbad-based IVD CDMO/CRO specialising in tailored lateral flow assay devices and readers, from concept through manufacturing. Comparable as a co-development partner and competitor in the custom integrated rapid test platform space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Atomo Diagnostics social profiles

Digital presence

Atomo Diagnostics compliance and trust

Trust signal

Compliance6 records

Atomo Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Atomo Diagnostics leadership team

Management profile

Number of profiles

Profiles5 records

Atomo Diagnostics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Atomo Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atomo Diagnostics

What does Atomo Diagnostics do?

Atomo Diagnostics designs, develops, and manufactures integrated, user-centred rapid diagnostic test (RDT) platforms and finished diagnostic products for point-of-care and consumer self-testing applications. Its AtomoRapid™ platform family integrates safety lancets, blood/swab collection, and patented buffer-delivery systems into all-in-one cassettes that reduce user error. The company sells its own Atomo HIV Self Test through e-commerce and pharmacies, supplies proprietary cassettes to OEM partners (Lumos Diagnostics, NG Biotech), and offers co-development, licensing, and contract manufacturing services from its ISO 13485-certified Cape Town facility.

Is Atomo Diagnostics a public or private company?

Atomo Diagnostics is a private company. It is classified as public and is currently operating.

When was Atomo Diagnostics founded?

Atomo Diagnostics was founded in 2010. It employs 11 to 50 people.

Where is Atomo Diagnostics based?

Atomo Diagnostics is headquartered in Leichhardt, Australia, in the Oceania region.

How does Atomo Diagnostics make money?

Four revenue lines are on record. Rapid Diagnostic Test Device Sales are the primary driver. The others are OEM Cassette Supply, technology Licensing and Co-Development and contract Manufacturing.

Who are Atomo Diagnostics's main competitors?

Direct peers on record are OraSure Technologies, Lumos Diagnostics, Chembio Diagnostics, NG Biotech and Trinity Biotech. Broad incumbents are Abbott (Rapid Diagnostics / BinaxNOW), QuidelOrtho and Roche Diagnostics. Emerging players are BBI Solutions and DCN Diagnostics.

Does Atomo Diagnostics have an API?

No public API is recorded for Atomo Diagnostics.

What industry is Atomo Diagnostics in?

Atomo Diagnostics's product category is In-Vitro Diagnostic Devices. Its primary akta.pro industry code is HLALAIAL, Infectious Disease & STI Testing-to-Treatment with eRx + Pharmacy Fulfillment. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooAtomo Diagnostics Ltd (ASX:AT1) (Q1 2027) Earnings Call Highlights: Revenue Surges 140% as HIV ...Atomo Diagnostics reported Q1 2027 revenue of $1.63 million, up 140% year over year, driven by HIV franchise growth of 38% and OEM revenue of $938,000, up over 450%. Gross margin fell to 26% from 38%, and EBITDA loss widened to $1.3 million. The company expects new product launches in about 18 months to improve margins and achieve breakeven.Investing.comEarnings call transcript: Atomo Diagnostics posts 140% revenue jump in Q1 2026Atomo Diagnostics reported Q1 2026 revenue of AUD 1.63 million, up 140% year over year, driven by HIV and OEM sales. Gross margin fell to 26% and EBITDA loss widened to AUD 1.3 million, while cash ended at AUD 2.67 million. Management plans product launches and margin improvements in the second half of the fiscal year.TradingViewAtomo Diagnostics Q1 2027 Earnings Call Is LiveAtomo Diagnostics' Q1 2027 earnings call is live, with executives discussing financial results and answering analyst questions. The call may include surprise news, and management commentary can move markets.TradingViewAtomo Diagnostics: Revenue surged as OEM growth and new diagnostic programs expanded the growth pipelineAtomo Diagnostics reported Q1 FY27 revenue up 140% year-over-year, driven by HIV growth and a sharp increase in OEM sales. Gross margin narrowed and EBITDA loss widened. New HIV, syphilis, and brain-disease programs advanced toward clinical, regulatory, and commercial milestones.Investing.comAtomo FY26 slides: revenue surges 41% amid CEO transition By Investing.comAtomo Diagnostics reported FY26 revenue of A$5.3 million, up 41% year-over-year, and appointed Dr. Cheri Walker as interim CEO. HIV franchise sales rose 21% to A$2.8 million, while OEM revenue surged 209% to A$2.2 million. Gross margins compressed to 35% from 51% as the company shifts toward lower-margin global health markets.Investing.comAtomo FY26 slides: 41% revenue growth, new CEO named By Investing.comAtomo Diagnostics reported fiscal 2026 revenue of A$5.3 million, up 41%, and narrowed its EBITDA loss by 39% to A$2.06 million. The company appointed Dr. Cheri Walker as interim CEO and highlighted growth in HIV and OEM segments, with new product pipelines including an active syphilis test.Investing.comAtomo Q4 FY26 slides: 40% revenue growth, expanding test portfolio By Investing.comAtomo Diagnostics presented its Q4 FY26 quarterly results on July 24, 2026, reporting full-year revenue of AUD 5.3 million, a 40% increase year-over-year, driven by HIV testing and OEM sales growth. The company ended the quarter with AUD 3.7 million in cash, no debt, and AUD 1.5 million in unfulfilled orders, while also advancing pipeline products including an active syphilis test and liver function test targeting significant unmet clinical needs.Investing.comEarnings call transcript: Atomo Diagnostics posts 40% FY 2026 revenue growth in Q4 2026 By Investing.comAtomo Diagnostics reported 40% revenue growth for FY 2026, reaching AUD 5.3 million, driven primarily by increased HIV self-testing sales and growth in its OEM Pascal platform, with Q4 revenue at AUD 2.3 million. The company ended the period with AUD 3.7 million in cash, zero debt, and AUD 1.5 million in unfulfilled orders carrying into FY 2027. Management outlined expansion plans including a 33% increase in active pharmacies in Australia and New Zealand, European market growth through partner Newfoundland, and new product development including active syphilis testing and liver function tests.TipranksAtomo Diagnostics Expands Point-of-Care Test Portfolio and Supply PartnershipsAtomo Diagnostics Ltd. has provided a business update highlighting expansion of its point-of-care rapid test portfolio, anchored by its market-leading HIV products in Australia, New Zealand, and the United Kingdom, while developing new assays for active syphilis and liver function. The company is deepening its role as a supply partner by providing proprietary cassettes to Lumos Diagnostics for the CLIA-waived FebriDx test and to NG Biotech for an IVDR-approved blood pregnancy test. These partnerships underscore growth prospects in global rapid testing markets, with new customers valuing the company's devices for usability and reliability.Investing.comAtomo Diagnostics Q2 FY26 slides: revenue doubles as product portfolio expands By Investing.comAtomo Diagnostics Ltd reported Q2 FY26 revenue of $1.5 million, representing a 121% quarter-over-quarter increase driven by HIV self-test business ($600,000) and OEM product sales ($820,000). The company secured strategic developments including a $500,000 HIV self-test order for Africa funded by the Global Fund, an exclusive global licensing agreement for a novel liver function test, and new customer acquisitions in the UK and Canada. Atomo maintains a cash position of $3.51 million with a 40% gross margin, positioning itself for continued growth in the point-of-care diagnostics market.